SPX3,821.74-9.65 -0.25%
DIA309.03-0.68 -0.22%
IXIC11,290.01-32.23 -0.28%

BRIEF-Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression After Single Ivt Injection Of Advm-022

reuters.com · 06/09/2022 08:15
BRIEF-Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression After Single Ivt Injection Of Advm-022

- Adverum Biotechnologies Inc ADVM:

  • ADVERUM BIOTECHNOLOGIES PRESENTS THREE-YEAR AFLIBERCEPT PROTEIN EXPRESSION AND IMPROVEMENT IN ANATOMIC OUTCOMES AFTER A SINGLE IVT INJECTION OF ADVM-022 IN THE OPTIC STUDY IN WET AMD

  • ADVERUM - 3-YEAR AFLIBERCEPT PROTEIN EXPRESSION SHOWS CONTINUOUS, CONSISTENT THERAPEUTIC LEVELS FROM ADVM-022 IN OPTIC STUDY SUBJECTS WITH WET AMD

Source text for Eikon: ID:nGNX12b369

Further company coverage: ADVM


((reuters.briefs@thomsonreuters.com;))